Print

MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I - MRX-I Targets Multi-Drug Resistant Gram Positive Infections  
3/15/2010 10:30:30 AM

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

MRX-I: A Safer Oxazolidinone Antibiotic

Multi-Drug Resistance: A Growing Global Public Health Crisis

About MicuRx Pharmaceuticals, Inc.

MicuRx Pharmaceuticals, Inc.




//-->